For the quarter ending 2026-03-31, BIO-B has $9,790,000K in assets. $2,938,700K in debts. $507,200K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Cash and cash equivalents | 507,200 | 529,800 | 395,800 | |
| Short-term investments | 1,057,500 | 1,010,900 | 1,022,800 | |
| Accounts receivable, net | 426,200 | 460,600 | 464,700 | |
| Inventory | 770,500 | 740,700 | 783,200 | |
| Prepaid expenses | 150,000 | 136,500 | 152,000 | |
| Other current assets | 30,700 | 27,700 | 23,500 | |
| Total current assets | 2,942,100 | 2,906,200 | 2,842,000 | |
| Property, plant and equipment, net | 527,500 | 539,900 | 540,200 | |
| Operating lease right-of-use assets | 161,900 | 170,000 | 180,300 | |
| Goodwill, net | 577,100 | 579,800 | 578,700 | |
| Purchased intangibles, net | 166,800 | 174,300 | 388,400 | |
| Other investments | 5,311,800 | 6,103,600 | 5,057,800 | |
| Other assets | 102,800 | 102,700 | 109,000 | |
| Assets | 9,790,000 | 10,576,500 | 9,696,400 | |
| Accounts payable | 133,100 | 129,000 | 128,800 | |
| Accrued payroll and employee benefits | 148,400 | 172,300 | 182,800 | |
| Current maturities of long-term debt and notes payable | 400,500 | 1,300 | 1,300 | |
| Income and other taxes payable | 44,900 | 36,600 | 44,800 | |
| Current operating lease liabilities | 36,200 | 36,100 | 36,800 | |
| Other current liabilities | 153,900 | 141,700 | 127,800 | |
| Total current liabilities | 917,000 | 517,000 | 522,300 | |
| Long-term debt, net of current maturities | 802,900 | 1,201,700 | 1,201,400 | |
| Deferred income taxes | 881,800 | 1,059,400 | 872,600 | |
| Operating lease liabilities | 138,600 | 145,700 | 155,800 | |
| Other long-term liabilities | 198,400 | 199,100 | 207,500 | |
| Total liabilities | 2,938,700 | 3,122,900 | 2,959,600 | |
| Preferred stock, value, issued | 0 | 0 | 0 | |
| Common stock-Common Class A | 0 | 0 | 0 | |
| Common stock-Common Class B | 0 | 0 | 0 | |
| Additional paid-in capital | 490,500 | 476,000 | 461,900 | |
| Class a treasury stock at cost, 3,275,476 shares at 2025 and 2,254,728 shares at 2024 | - | 1,009,600 | - | |
| Treasury stock-Treasury Stock Common | 1,053,000 | - | 1,014,600 | |
| Retained earnings | 7,649,200 | 8,176,300 | 7,456,300 | |
| Accumulated other comprehensive loss | -235,400 | -189,100 | -166,800 | |
| Total stockholders' equity | 6,851,300 | 7,453,600 | 6,736,800 | |
| Total liabilities and stockholders' equity | 9,790,000 | 10,576,500 | 9,696,400 | |
BIO-RAD LABORATORIES, INC. (BIO-B)
BIO-RAD LABORATORIES, INC. (BIO-B)